Copyright
©The Author(s) 2025.
World J Transplant. Jun 18, 2025; 15(2): 98055
Published online Jun 18, 2025. doi: 10.5500/wjt.v15.i2.98055
Published online Jun 18, 2025. doi: 10.5500/wjt.v15.i2.98055
Table 1 Characteristics of the study population used for the meta-analysis on cyst progression
Agarwal et al[9], 2016 | |
Patients n (IS/ control) | 26/26 |
Mean Age in years (IS/control) | 60/63 |
Reason for IS | Solid organ transplantation (35.9%), autoimmune disorders (33.3%), inflammatory bowel disease (15.4%), other conditions (15.4%) |
Follow up in months (IS/control) | 24.3/21.5 |
Type of included cysts | IPMN, MCN |
Primary outcome | 1. Obstructive jaundice in a patient with cystic lesion of the head of the pancreas |
2. Enhancing solid components within the cyst | |
3. Main pancreatic duct diameter measuring 10 mm or larger | |
4. Cyst progression to 30 mm or larger | |
5. Development of thickened/enhancing cyst walls | |
6. Increase of main pancreatic duct size 5-9 mm | |
7. Development of non-enhancing mural nodules | |
8. Abrupt change in caliber of the pancreatic duct with distal pancreatic atrophy | |
Dorfman et al[8], 2016 | |
Patients n (IS/control) | 16/131 |
Mean age in years (IS/control) | 61/70 |
Type of included cysts | IPMN |
Reason for IS | Liver transplantation |
Follow up in months (IS/control) | 31/31 |
Primary outcome | Development of: |
1. Presence of mural nodules | |
2.Cyst size of ≥ 30 mm | |
3. Thickened cyst walls | |
4. Pancreatic duct diameter of 5 to 9 mm | |
5. Abrupt change in the duct caliber with distal pancreatic atrophy and lymphadenopathy | |
Gill et al[19], 2009 | |
Patients n (IS/control) | 33/57 |
Mean age in years (IS/control) | 63/68 |
Reason for IS | Solid organ transplantation [liver (81.8%), kidney (15.2%), heart (3.0%)] |
Follow up in months (IS/control) | 29/28 |
Type of included cysts | IPMN |
Primary outcome | Consensus indication for resection (i.e., cyst-related symptoms, cyst size > 30 mm, mural nodules, positive cytology) |
Lennon et al[10], 2014 | |
Patients n (IS/control) | 23/274 |
Mean age in years (IS/control) | 56.8/63.7 |
Reason for IS | Liver transplantation |
Follow up in months (IS/control) | 53.7/24 |
Type of included cysts | IPMN |
Primary outcome | 1. Jaundice secondary to the pancreatic cyst |
2. Mural nodule or solid component within the cyst | |
3. Cytology suspicious or diagnostic for malignancy | |
4. Cyst diameter 3 cm | |
5. Main pancreatic duct involvement (pancreatic duct diameter 5 mm) |
- Citation: Kießler M, Friess H, Assfalg V. Prevalence and risk of progression of pancreatic cystic lesions in immunosuppressed patients: A systematic review and meta-analysis. World J Transplant 2025; 15(2): 98055
- URL: https://www.wjgnet.com/2220-3230/full/v15/i2/98055.htm
- DOI: https://dx.doi.org/10.5500/wjt.v15.i2.98055